Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives.

Mol Cancer · 2025 · PMC12604315 · PMID 41214710

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

The NCT03342911 trial showed a 45% pCR and 73% MPR with a significant trend towards survival benefit, with a 3-year OS of 83% and recurrence-free survival (RFS) of 74%.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.